HOME
Leading the way to a cure

Lupus Research Update: 2013 Volume 1

Volume 1, 2013 - Online Edition | In This Issue


Making the Connection Between Cardiovascular Disease and Lupus >
The ALR Welcomes New Board Member Daniel LaVecchia >
Two Compassionate Hearts Work to End Lupus >
2013 ALR TIL Grants Awarded >
Lupus News Corner >

2013 ALR TIL Grants Awarded

The ALR is pleased to announce the recipients of our latest Target Identification in Lupus (TIL) grants. "The ALR believes that this year's TIL grantees will advance the science and medicine of lupus. We congratulate this distinguished group of scientists and look forward to reviewing their findings," said Dr. Mary Crow, Chair of the ALR's Scientific Advisory Board.

2013 TIL Grantees

Anne Davidson, MBBS
The Feinstein Institute for Medical Research
Inhibition of IL-6 trans-signaling in SLE

Laurie Davis, PhD
UT Southwestern Medical Center
TREM-1 in Lupus Nephritis

Michael Holers, MD
University of Colorado, Denver, AMC and DC
The CR2:C3d Receptor: Ligand Interaction as Therapeutic Target in Lupus

Michael Karin, PhD
University of California, San Diego
New Targets for Treatment of Glucocorticoid-resistant Lupus

Gang Lin, PhD
Joan & Stanford I. Weill Medical College of Cornell University
Immunoproteasome Selective Inhibitors for Lupus Treatment

Laurence Morel, PhD
University of Florida
CD4 T Cell Metabolism in SLE: Characterization and Target Identification

Fred Perrino, PhD
Wake Forest University Health Science
Targeting DNA Polynucleotides in Lupus

William Stohl, MD, PhD
University of Southern California
The Roles of the Individual Elements of the BAFF Axis in Murine SLE

Barbara Vilen, PhD
University of North Carolina at Chapel Hill
The Role of Immune Complexes and BAFF in Promoting Atherosclerosis in Lupus

TIL Grant Mechanism Is Expanded

The ALR's highly successful two-year grant mechanism — Target Identification in Lupus (TIL) — just got better.

Scientists who are delivering promising results now have a chance to continue their investigations through a third-year grant extension.

“Lupus is a very complex disease to diagnose, treat and defeat... and the ALR wants to propel the work of our most talented investigators,” said Kenneth M. Farber, ALR President. “We're in a position — thanks to the generous support of our donors — to offer, for the first time, third-year funding to the best of the best... and that's going to advance the quest for a cure.”

The ALR is expecting great things. Third-year funding is based on past success, which is reviewed by the ALR's Scientific Advisory Board. Work of the most innovative, pioneering scientists will receive third-year awards of up to $200,000.

In the first year of this new extension program, 10 TIL grantees have been selected for third-year funding with grants totaling $1.9 million.


1.5 million

people in the U.S. have Lupus.

90 million

dollars committed to lupus research by the Alliance for Lupus Research.


We're walking across the United States to raise awareness and funds for lupus research.

Can't make it? Join our National Virtual Walk to participate anytime, anywhere.


Show your support by visiting the Alliance for Lupus Research online store. Discover the perfect gift, or prepare for a walk with our selection of apparel and accessories.